Recognizing Public Goods in WTO Disputes Settlement: Who Participates? Who Decides? The Case of TRIPS and Pharmaceutical Patent Protection
University of California, Irvine School of Law
Journal of International Economic Law, Vol. 7, No. 2, pp. 459-482
The question of how to produce 'global public goods' in a world of soveriegn states with divergent norms and preferences, reflecting differences in economic development levels, is increasingly on the international policy agenda. This is an issue not only for political decision-making but also for judicial interpretation of existing international agreements. This article analyzes this fundamental question in the context of the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) of the World Trade Organization (WTO), with particular emphasis on patent protection for pharmaceutical products. The TRIPS Agreement's provisions raise concerns over at least three public (or quasi-public) goods in this area: the generation of new knowledge, the provision of public health, and the maintenance of rules fostering open trade and competition. WTO judicial panels charged with resolving disputes regarding medicines patents must determine whether to defer to national sovereignty, multilateral negotiations, or their own interpretations in balancing among these objectives. This, questions of 'who participates' and 'who decides' will be critical in this determination. The article notes structural weakness in the ability of developing countries to participate meaningfully in this process and offers suggestions for making their participation more meaningful so as to protect their interests.
Number of Pages in PDF File: 24
Keywords: WTO, TRIPS, pharmaceutical, trade, judicial interpretation, developing countries, public goodsAccepted Paper Series
Date posted: April 12, 2004
© 2015 Social Science Electronic Publishing, Inc. All Rights Reserved.
This page was processed by apollo5 in 0.297 seconds